|
Primary Myelofibrosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
AURKA expression did not significantly differ between myelofibrosis and controls (P = 0.466).
|
31837568 |
2020 |
|
Myelofibrosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
AURKA expression did not significantly differ between myelofibrosis and controls (P = 0.466).
|
31837568 |
2020 |
|
Chronic myeloproliferative disorder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
AURKA contributes to Janus-kinase-2 (JAK2) activation and increased AURKA protein levels were reported in CD34+ and CD41+ cells of myeloproliferative neoplasm patients, leading to aneuploidy and aberrant megakaryopoiesis.
|
31837568 |
2020 |
|
Myeloproliferative disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
AURKA contributes to Janus-kinase-2 (JAK2) activation and increased AURKA protein levels were reported in CD34+ and CD41+ cells of myeloproliferative neoplasm patients, leading to aneuploidy and aberrant megakaryopoiesis.
|
31837568 |
2020 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
|
Glioblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
|
Childhood Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that AURKA and KDR genes are hub driver genes in glioblastoma with bioinformatics technology including WGCNA analysis, PPI network, GO, KEGG analysis and GSEA analysis.
|
31706255 |
2019 |
|
Glioblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
We show that AURKA and KDR genes are hub driver genes in glioblastoma with bioinformatics technology including WGCNA analysis, PPI network, GO, KEGG analysis and GSEA analysis.
|
31706255 |
2019 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We show that AURKA and KDR genes are hub driver genes in glioblastoma with bioinformatics technology including WGCNA analysis, PPI network, GO, KEGG analysis and GSEA analysis.
|
31706255 |
2019 |
|
Childhood Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We show that AURKA and KDR genes are hub driver genes in glioblastoma with bioinformatics technology including WGCNA analysis, PPI network, GO, KEGG analysis and GSEA analysis.
|
31706255 |
2019 |
|
Malignant tumor of cervix
|
0.020 |
Biomarker
|
disease |
BEFREE |
In addition, AURKA was confirmed as a direct target of miR-149-5p in cervical cancer and positively regulated by hsa_circ_0075341.
|
31706100 |
2020 |
|
Cervix carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In addition, AURKA was confirmed as a direct target of miR-149-5p in cervical cancer and positively regulated by hsa_circ_0075341.
|
31706100 |
2020 |
|
cervical cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
In addition, AURKA was confirmed as a direct target of miR-149-5p in cervical cancer and positively regulated by hsa_circ_0075341.
|
31706100 |
2020 |
|
Pancreatic carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Here, we tested two drugs displaying dual inhibitory activity towards PDK1 and Aurora kinase A in a panel of pancreatic cancer cell lines and in two in vivo models of pancreatic cancer.
|
31683659 |
2019 |
|
Malignant neoplasm of pancreas
|
0.090 |
Biomarker
|
disease |
BEFREE |
Here, we tested two drugs displaying dual inhibitory activity towards PDK1 and Aurora kinase A in a panel of pancreatic cancer cell lines and in two in vivo models of pancreatic cancer.
|
31683659 |
2019 |
|
Cervical Squamous Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, a total of four DEGs (TYMS, SASH1, CDK1 and AURKA) and two DEmiRNAs (hsa-miR-21 and hsa-miR-99a) may be involved in the pathogenesis of CIN and the progression of CIN into CSCC.
|
31642613 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, a total of four DEGs (TYMS, SASH1, CDK1 and AURKA) and two DEmiRNAs (hsa-miR-21 and hsa-miR-99a) may be involved in the pathogenesis of CIN and the progression of CIN into CSCC.
|
31642613 |
2019 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
|
31617432 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neither baseline tumor expression of AURKA (ROC = 0.57, P = 0.46) nor AURKB (ROC = 0.56, P = 0.87) predicted for ypT2-4 status.
|
31597600 |
2019 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder.
|
31597600 |
2019 |
|
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder.
|
31597600 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Suppression of aurora kinase A could lead to lower cell proliferation and higher doxorubicin sensitivity of hepatocellular carcinoma cells.
|
31570091 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In cancer-like contexts, AURKA actively promotes DNA repair, it acts as a transcription factor, promotes cell migration and invasion, and it localises at mitochondria to regulate mitochondrial dynamics and ATP production.
|
31562563 |
2020 |